Ocular Therapeutix targets Q4 2026 wet AMD NDA submission
The company plans to submit its AXPAXLI NDA for wet AMD in Q4 2026 and reported a balance of $598.6M to support commercialization efforts.
View filing at SEC.gov →1 most recent filing and news item mentioning OCUL. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/OCUL/news?limit=20"
Pull OCUL filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayThe company plans to submit its AXPAXLI NDA for wet AMD in Q4 2026 and reported a balance of $598.6M to support commercialization efforts.
View filing at SEC.gov →